Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs S&P500 ETF (SPY) Price & Performance

BioNano Genomics IncTrade
S&P500 ETFTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs S&P500 ETF — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while S&P500 ETF trades at $754.7. The key difference: S&P500 ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

BNGOSPY
Market Cap
$13.20M
Sector
Health
52-Week High
$4.92$759.55
52-Week Low
$1.09$621.75
Enterprise Value
$15.81M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

S&P500 ETF

SPY trades at $749.08, down 0.77% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF approaches key resistance at $750 with support at $747. Recent news highlights analyst optimism with several firms projecting S&P 500 targets above 8,000 by year-end, though earnings season and inflation data remain key catalysts.

Outlook remains constructive given strong institutional sentiment and historical market performance, though risks include potential Fed policy shifts and valuation concerns. The dividend payment scheduled for July 31, 2026 provides income support, while technical consolidation near all-time highs suggests potential for breakout momentum if earnings deliver.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on SPY